Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Allstate Sees Q4 Adj. Net Loss $335M-$385M

Allstate Sees Q4 Adj. Net Loss $335M-$385M

-SEC Filing

byMichael Horton

January 18, 2023

1 minute read

-SEC Filing

Morgan Stanley Downgrades Motorola Solns to Equal-Weight, Raises Price Target to $260

By Benzinga Newsdesk

September 14, 6:10 AM

Morgan Stanley analyst Erik Lapinski downgrades Motorola Solns (NYSE:MSI) from Overweight to Equal-Weight and raises the price target from $240 to $260.

MSI

Panbela Therapeutics (PBLA) Stock Is Down 25%: What’s Going On?

By Henry Khederian

December 20, 2:37 PM

Panbela Therapeutics Inc (NASDAQ: PBLA) shares are trading lower by 25% to $1.18 Wednesday afternoon, pulling back following recent, marked strength.

PBLA

Clovis Oncology’s Rubraca Hits Primary Goal In Prostate Cancer Settings

By Vandana Singh

October 3, 1:35 PM

Clovis Oncology Inc (NASDAQ:CLVS) announced topline data from the Phase 3 TRITON3 trial, demonstrating that Rubraca monotherapy treatment significantly improved radiographic…

CLVS

Greenlane To Distribute Vaporization Brand AUXO By CCELL Via New Partnership

By Jelena Martinovic

October 13, 9:54 AM

Greenlane Holdings, Inc. (NASDAQ: GNLN) announced on Thursday its distribution partnership with AUXO, an innovative vaporization brand produced by SMOORE.

GNLN

Allstate Sees Q4 Adj. Net Loss $335M-$385M

Related Posts

Morgan Stanley Downgrades Motorola Solns to Equal-Weight, Raises Price Target to $260

Panbela Therapeutics (PBLA) Stock Is Down 25%: What’s Going On?

Clovis Oncology’s Rubraca Hits Primary Goal In Prostate Cancer Settings

Greenlane To Distribute Vaporization Brand AUXO By CCELL Via New Partnership